Medpace Holdings Inc. logo

Medpace Holdings Inc. (01P)

Market Open
14 Oct, 07:57 PM
XSTU XSTU
€
552. 20
+8
+1.47%
€
- Market Cap
35.12 P/E Ratio
- Div Yield
4 Volume
8.64 Eps
€ 544.2
Previous Close
Add Transaction
Day Range
539.2 564.2
Year Range
334 564.2
Want to track 01P and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

01P trading today higher at €552.2, an increase of 1.47% from yesterday's close, completing a monthly increase of 1.3211% or €7.2. Over the past 12 months, 01P stock gained 16.1304%.
01P is not paying dividends to its shareholders.
The last earnings report, released on Apr 20, 2026, missed the consensus estimates by -4.01%. On average, the company has fell short of earnings expectations by -2.7467%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

01P Chart

Medpace (MEDP) Dips More Than Broader Market: What You Should Know

Medpace (MEDP) Dips More Than Broader Market: What You Should Know

In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.

Zacks | 2 days ago
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One

Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One

Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer against potential cash flow volatility as biotech funding rebounds.

Seekingalpha | 2 days ago
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.

Zacks | 1 week ago

Medpace Holdings Inc. (01P) FAQ

What is the stock price today?

The current price is €552.20.

On which exchange is it traded?

Medpace Holdings Inc. is listed on XSTU.

What is its stock symbol?

The ticker symbol is 01P.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Medpace Holdings Inc. ever had a stock split?

No, there has never been a stock split.

Medpace Holdings Inc. Profile

Professional Services Industry
Industrials Sector
August James Troendle CEO
XSTU Exchange
58506Q109 CUSIP
US Country
6,500 Employees
- Last Dividend
- Last Split
11 Aug 2016 IPO Date

Overview

Medpace Holdings, Inc., founded in 1992 and headquartered in Cincinnati, Ohio, is a key player in the provision of comprehensive clinical research services for the development of drugs and medical devices. Spanning its operations across North America, Europe, and Asia, the company supports pharmaceutical, biotechnology, and medical device industries through the entire clinical development process, from Phase I to Phase IV, across a wide range of therapeutic areas. Its aim is to facilitate the journey of bringing new and innovative treatments to market efficiently and effectively.

Products and Services

  • Development Plan Design: Crafting bespoke development strategies addressing specific therapeutic area requirements and regulatory landscapes to streamline the development process from concept to market.
  • Coordinated Central Laboratory: Offering centralized lab services that reduce logistical complexities, enhance data quality, and streamline sample management across global trial sites.
  • Project Management: Delivering comprehensive project oversight to ensure milestones are met on time and within budget while maintaining adherence to regulatory standards.
  • Regulatory Affairs: Providing expertise in navigating the complex regulatory environment to facilitate timely approval from regulatory bodies.
  • Clinical Monitoring: Ensuring the integrity of clinical trial data through close site monitoring, including site selection, training, and ongoing assessment for adherence to protocols.
  • Data Management and Analysis: Implementing rigorous processes for data collection, validation, and analysis to support statistical significance and findings of clinical trials.
  • Pharmacovigilance: Monitoring and managing the safety profile of drugs through all phases of clinical trials to ensure patient safety and regulatory compliance.
  • New Drug Application Submissions: Assisting in the preparation and submission of documentation required for the approval of new drugs, ensuring accuracy and regulatory compliance.
  • Post-Marketing Clinical Support: Offering services to monitor a drug's performance and safety after it has been approved and is in the market to fulfill post-marketing requirements and commitments.
  • Bio-Analytical Laboratory Services: Providing state-of-the-art laboratory services to support the analysis of biological samples, which is crucial for understanding the pharmacokinetics and pharmacodynamics of a drug.
  • Clinical Human Pharmacology: Conducting early phase clinical trials, including first-in-human studies, to assess the safety, tolerability, and pharmacokinetics of a drug.
  • Imaging Services: Utilizing advanced imaging technologies to enhance understanding of a drug's mechanism of action and contribute to endpoint assessments in clinical trials.
  • Electrocardiography (ECG) Reading Support: Offering expert ECG analysis to detect potential cardiac risks in clinical trial participants, enhancing patient safety throughout the trial process.

Contact Information

Address: 5375 Medpace Way
Phone: 513 579 9911